The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IPIG 2025 | Managing breakthrough hemolysis in patients on complement inhibitor treatment for PNH
In this video, Jaroslav Čermák, MD, Institute of Hematology and Blood Transfusion (ÚHKT), Prague, Czechia, highlights that breakthrough hemolysis is a commonly observed adverse event when treating patients with paroxysmal nocturnal hemoglobinuria (PNH) using complement inhibitors and briefly outlines the management of this complication. This interview took place at the 2nd International PNH Interest Group (IPIG) Conference in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It’s breakthrough hemolysis. We observed breakthrough hemolysis in about 20% of the patients. Both patients on C3 and C5 inhibitors. How to manage the patients? For patients who are on terminal complement inhibitors, we are usually giving them one additional dose of the drug of the C5 inhibitor. For patients with C3 inhibitors, we have two options, just to increase the dose of C3 inhibitors by extra injections, one or two injections, or to give them an extra injection of C5 inhibitors...
It’s breakthrough hemolysis. We observed breakthrough hemolysis in about 20% of the patients. Both patients on C3 and C5 inhibitors. How to manage the patients? For patients who are on terminal complement inhibitors, we are usually giving them one additional dose of the drug of the C5 inhibitor. For patients with C3 inhibitors, we have two options, just to increase the dose of C3 inhibitors by extra injections, one or two injections, or to give them an extra injection of C5 inhibitors.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
